Nanoscope Therapeutics
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Nanoscope Therapeutics sits in the upper quartile of US sponsors by registered trial count (#2,085 of 15,742 sponsors by registered trial count).
Nanoscope Therapeutics: 6 sponsored US clinical trials, 1 recruiting.
Nanoscope Therapeutics sponsors 6 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 3 completed. 0 of these trials are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Retinitis Pigmentosa, with 3 trials.
Upper-quartile sponsor footprint
Nanoscope Therapeutics sits in the upper quartile of the sponsor corpus (#2,085 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
6 total, page 1 of 1
A Prospective Observational Study to Assess the Reliability and Validity of the MLSDT
NCT06805474
Non-Interventional Long Term Follow-up Study of Participants Previously Enrolled in the RESTORE Study
NCT06162585
Non-interventional Long Term Follow-up Study of Participants Previously Enrolled in the STARLIGHT Study
NCT06048185
Observational Study to Assess the Reliability and Validity of the MLYMT and MLSDT
NCT05820100
Safety and Effects of a Single Intravitreal Injection of vMCO-010 Optogenetic Therapy in Subjects With Stargardt Disease
NCT05417126
Efficacy and Safety of MCO-010 Optogenetic Therapy in Adults With Retinitis Pigmentosa [RESTORE]
NCT04945772
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 2 |
Therapeutic Areas
What is open in the Nanoscope Therapeutics pipeline
1 recruiting of 6 indexed (17% open); 3 completed (50%).
Phase mix: 0 late (III/IV) vs 2 early (I/II) (early-phase heavy).
Top condition: Retinitis Pigmentosa (3 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Nanoscope Therapeutics: open-pipeline peers nationwide
Peers matched on 6 registered trials and 17% open enrollment, not the therapeutic-area sidebar.
Nanoscope Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 6 trials (± recruiting share)
- 23andMe · 6 trials · 0% recruiting
- Aardvark Therapeutics · 6 trials · 0% recruiting
- Abbisko Therapeutics Co · 6 trials · 67% recruiting
- AbGenomics B.V Taiwan Branch · 6 trials · 0% recruiting
Sponsors near 17% open enrollment (± trial volume)
- Adagene · 17% recruiting · 6 trials
- Agendia · 17% recruiting · 6 trials
- Akamis Bio · 17% recruiting · 6 trials
- Angiodynamics · 17% recruiting · 12 trials
Related
What to do with this Nanoscope Therapeutics page
6 registered trials is a research-attention snapshot, not an endorsement of Nanoscope Therapeutics or any single study.
- 1 of Nanoscope Therapeutics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Retinitis Pigmentosa is the condition Nanoscope Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Retinitis Pigmentosa trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Nanoscope Therapeutics pipeline card: 6 registered trials from official public datasets.Report a data error.